The Non-Mevalonate Pathway to Isoprenoid Biosynthesis:A Potential Source of New Drug Targets by Hirsch, Anna K.H. & Diederich, François
  
 University of Groningen
The Non-Mevalonate Pathway to Isoprenoid Biosynthesis





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hirsch, A. K. H., & Diederich, F. (2008). The Non-Mevalonate Pathway to Isoprenoid Biosynthesis: A
Potential Source of New Drug Targets. Chimia, 62(4), 226-230. https://doi.org/10.2533/chimia.2008.226
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
LAUREATES: AWARDS AND HONORS SCS FALL MEETING 2007 226
CHIMIA 2008, 62, No. 4
Chimia 62 (2008) 226–230
© Schweizerische Chemische Gesellschaft
ISSN 0009–4293
The Non-Mevalonate Pathway to
Isoprenoid Biosynthesis:
A Potential Source of New Drug Targets




SCS Mettler-Toledo Award Winner (Oral Presentation)
Dedicated to Professor Andreas Pfaltz on the occasion of his 60th birthday
Abstract: Isoprenoids are an essential class of natural products with a myriad of biological functions. All iso-
prenoids are assembled using two common five-carbon precursors, isopentenyl diphosphate (IPP) and dimethyl-
allyl diphosphate (DMAPP) that are biosynthesized via two completely independent routes: the mevalonate and
the non-mevalonate pathway. While the former is used by humans, the latter is employed exclusively by a number
of important pathogens such as the malarial Plasmodium falciparum parasite or the tuberculosis-causing Myco-
bacterium tuberculosis bacterium. Hence, the constituent enzymes are potentially very interesting drug targets
in the ongoing fight against diseases, whose treatment has been complicated by the emergence of multi-drug
resistance. After a short description of the biosynthetic pathway, an overview will be given on the known inhibitors
of the individual enzymes.
Keywords: Anti-infective agents · Drug design · Inhibitors · Isoprenoid biosynthesis · Non-mevalonate pathway
post-translational processes. In spite of
their striking structural diversity, all iso-
prenoids are biosynthesized from the same,
rather simple two five-carbon building
blocks, isopentenyl diphosphate (IPP) and
dimethylallyl diphosphate (DMAPP). Until
recently, only one route to these precursors
was known, the so-called mevalonate path-
way.
[1]
In the early 1990s, an alternative to
this well-established biosynthetic route was
discovered. It is now known as the non-me-
valonate, 1-deoxy-D-xylulose-5-phosphate
(DXP), or 2C-methyl-D-erythritol (MEP)
pathway.
[2]
Interestingly, the two pathways are very
clearly distributed amongst organisms. On
the one hand, the mevalonate pathway is
used by most eukaryotes (importantly all
mammals), a few eubacteria, fungi, the cy-
tosol and mitochondria of plants, as well




pathway, on the other hand, provides the
precursors in algae, cyanobacteria, most
eubacteria, chloroplasts of plants and api-
complexan parasites.
[4]
The fact that the non-mevalonate
pathway is exclusively used by important
pathogens and not by humans means that
the constituent enzymes may be new attrac-
tive drug targets. Accordingly, the past two
decades witnessed intense research activity
aimed at the elucidation of the structures
and mechanisms of the involved enzymes.
Today, most of the structures have been
solved and detailed mechanistic data exist.
[5]
In particular, the component enzymes have
been genetically validated as drug targets.
[6]
The emergence of multi-drug resistance
both of the malarial parasites and the tuber-
culosis-causing bacteria has driven research
to identify anti-infectives with a novel
mode of action.
[7,8]
To achieve this, a num-
ber of the enzymes of the non-mevalonate
pathway have been chosen as targets. This
mini-review will give an update on each of
the enzymes, for which inhibitors or clini-
cal candidates are known.
2. Biosynthetic Route
In contrast to the mevalonate pathway
that exclusively uses two-carbon building
blocks, the non-mevalonate pathway uti-
lizes two-carbon and three-carbon building
blocks for the biosynthesis of the isoprenoid
precursors IPP and DMAPP. These are as-
sembled by the action of a total of seven en-
zymes (Scheme). As shown by deuterium-
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1. Introduction
Isoprenoids form an extremely large and
diverse class of natural products. The more
than 35,000 members of the isoprenoid
group fulfill a number of important bio-
logical functions, including protein degra-
dation, meiosis, apoptosis, electron trans-
port and regulation of transcription and
doi:10.2533/chimia.2008.226
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labelling studies, IPP and DMAPP are both
generated in the last enzymatic reaction.
[9]
In spite of this, one of the two types of IPP
isomerase (EC 5.3.3.2) can be present as an
eighth enzyme in species utilizing the non-
mevalonate pathway but it was shown not to





The non-mevalonate pathway starts
with the head-to-tail condensation of glyc-
eraldehyde 3-phosphate and pyruvate via a
thiamine-pyrophosphate-dependent decar-
boxylation catalyzed by 1-deoxy-D-xylu-
lose-5-phosphate synthase (EC 2.2.1.7).
[11]
Two inhibitors are known of the first en-
zyme. 5-Ketoclomazone (1), a metabolite
of the known herbicide clomazone (2), has
an IC
50




itself does not inhibit DXS, implying that
the breakdown product 1 might be the ac-
tive agent showing the herbicidal activity.
Fluoropyruvate (3) has IC
50
values of
400 µM and 80 µM for DXS from Pseudomo-
nas aeruginosa and E. coli, respectively
(Fig. 1).
[13]
It is supposed that fluoropyru-




The second enzyme of the pathway,
1-deoxy-D-xylulose 5-phosphate reductoi-
somerase (EC 1.1.1.267), catalyzes both the
rearrangement and reduction of 1-deoxy-D-




(4) and the acetyl derivative FR-900098 (5)
were the first reported inhibitors of the non-
mevalonate pathway and were identified to
inhibit IspC (Fig. 2). They were discovered
through a database search aimed at the iden-
tification of compounds active against bac-
teria utilizing the non-mevalonate pathway




and 5 were characterized as highly potent,
slow, tight-binding inhibitors with a good




cin was shown to cure malaria in rodents.
[17]
As combinations of 4 with the existing an-
timalarials clindamycin or artesunate are
even more efficient, they are currently be-
ing tested in clinical trials.
[18]
The fact that fosmidomycin is a very
cheap and safe drug that is well tolerated and
has high efficacy makes it a very promising
candidate for standard treatment in regions
where resistance against the recommended
sulfadoxine–pyrimethamine combination
is growing or where the price of the superi-
or artemisinin combinations is the limiting
factor. X-ray crystal structure analysis veri-
fied the binding mode of fosmidomycin. A
co-crystal structure of 4 and E. coli IspC
could be solved in complex with a Mn
2+
cation (PDB code: 1OPN). Fosmidomycin
was shown to bind in an analogous manner
to the substrate (Fig. 3).
[19]
The phospho-
nate group is bound by the polar or charged
amino acids Ser186, Ser222, Asn227 and
Lys228. The (N-formyl-N-hydroxy)amino
moiety is held in place through a chelat-
ing interaction with the co-crystallized
Mn
2+
cation using the O atom of both the
formyl and the N-hydroxy group. A crystal-

































































































































































Scheme. The non-mevalonate pathway for the biosynthesis of IPP and DMAPP. CDP-ME =
4-diphosphocytidyl-2C-methyl-D-erythritol, CDP-ME2P = 4-diphosphocytidyl-2C-methyl-D-erythritol
2-phosphate, DMAPP = dimethylallyl diphosphate, DOXP = 1-deoxy-D-xylulose 5-phosphate,
HMBPP = 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate, IPP = isopentenyl diphosphate, ME-
4P = 2C-methyl-D-erythritol 4-phosphate, MECDP = 2C-methyl-D-erythritol 2,4-cyclodiphosphate.
DXS = 1-deoxy-D-xylulose-5-phosphate synthase (EC 2.2.1.7), IspC = 1-deoxy-D-xylulose-5-
phosphate reductoisomerase (EC 1.1.1.267), IspD = 4-diphosphocytidyl-2C-methyl-D-erythritol
synthase (EC 2.7.7.60), IspE = 4-diphosphocytidyl-2C-methyl-D-erythritol kinase (EC 2.7.1.148),
IspF = 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (EC 4.6.1.12), IspG = 2C-methyl-D-
erythritol 2,4-cyclodiphosphate reductase (EC 1.17.4.3), IspH = 1-hydroxy-2-methyl-2-(E)-butenyl-




















= 0.4 mM (P. aeruginosa)
IC
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= 0.08 mM (E. coli)
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value is given as no K
i
value has been published.
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of Asp150, Glu152 and Glu231 provide the




Several derivatives of 4 and 5 were
conceived to improve the binding affin-
ity, achieve a better understanding of the
binding mode and optimize the drug-like
properties (Fig. 2).
[20]
Woo et al. analyzed
a series of systematically modified deriva-
tives. While replacement of the phospho-
nate moiety by a phosphate group led to
even more potent inhibitors (compounds
6a,b), however at the cost of pharmacoki-
netic stability,
[20e]
introduction of a car-
boxylate or sulfamate group (compounds
6c,d) produced a decrease in affinity. The
reduced affinity of the N-methyl analogue
6e suggests that the Mn
2+
-coordinating N-
hydroxy moiety (expectedly) makes a sub-
stantial contribution to the binding of fos-
midomycin. Van Calenbergh and coworkers
found that rigidification of the rather flex-
ible propyl linker using a cyclopropyl ring
(in (1R,2S)-7) did not enhance but rather
reduced the binding affinity as compared
to 4.
[20f]
Introduction of aromatic rings α to
the phosphonate moiety led to one inter-
esting derivative (±)-8 with a comparable
K
i
value to fosmidomycin against E. coli
IspC but a significantly enhanced activity
in the in vitro assay with intraerythrocytic
P. falciparum strains.
[20d]
Link and coworkers introduced aden-
osine derivatives, such as compound 9, in
another approach towards antimalarials.
It was suggested that this type of inhibi-
tor binds, amongst others, to the NADPH-
binding site of IspC.
[20a]
In addition, Walker
and Poulter presented substrate analogues
with IC
50




were identified as inhibitors of IspC with
IC
50
values in the single digit micromolar
range.
[20b]
No inhibitors of IspD, the third




The central enzyme of the non-me-
valonate pathway, 4-diphosphocytidyl-2C-
methyl-D-erythritol kinase (EC 2.7.1.148),
phosphorylates 4-diphosphocytidyl-2C-




The first inhibitors of this kinase
were recently reported by Hirsch et al. Us-
ing structure-based design, they were de-
veloped to target the cytidine- (of CDP-ME,
see Scheme) rather than the adenosine- (of
ATP) binding pocket, in order to achieve
selectivity against other kinases.
Thefirst-generationinhibitors(±)-10a–e
and (±)-11a–f (Fig. 4a) of E. coli IspE
achieved K
i
values in the nanomolar range
without the need for a phosphate or ribose
moiety. The introduction of phosphate or
phosphonate groups was avoided in order
to enhance the drug-like character of the
ligands. They feature a central cytosine
scaffold decorated with different ribose
substitutes (in (±)-10a–e) and a rather rigid
propargylic sulfonamide linker, directing
its alkyl substituent into a small, rather hy-
drophobic pocket lined by Phe185, Leu15
and Leu28. This pocket is not occupied by
either substrate or cofactor. The most potent
inhibitor to date (compound (±)-11a, K
i
=
290 nM) features a tetrahydrothiophenyl
ring as ribose analogue and a cyclopropyl




binding mode of (±)-11a is illustrated in
Fig. 4b. The cytosine scaffold of (±)-11a
is postulated to be sandwiched between
Tyr25 and Phe185 and to form three hy-
drogen bonds to both the backbone and the
side chain of His26. The tetrahydrothiophe-
nyl ring is stabilized by being sandwiched
between the rings of Pro182 and Tyr25. Ac-
cording to the modeling, both enantiomers
seem to fit equally well into the active site
and the S atom of the tetrahydrothiophenyl
ring seems to engage in a beneficial S
...
aro-
matic interaction with the phenolic ring of
Tyr25. The sulfonamide moiety is proposed
to form hydrogen bonds to the catalytically
Fig. 3. Co-crystal structure of fosmidomycin and
E. coli IspC (PDB code: IONP).
[19]
Color code:
protein skeleton: C: gray; inhibitor skeleton: C:





O: red sphere. Hydrogen-bond
distances are given in Å.
Fig. 4. a) Inhibitors of IspE. b) Proposed, computer modeling-based binding mode of (±)-11a in the
active site of E. coli IspE (PDB code: 1OJ4).
[22]
Color code as in Fig. 3, with S: yellow. Shown are
intermolecular hydrogen bonds to His26, as well as close S
...
aromatic and apolar contacts. Distances
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important residues Lys10 and Asp144; in-
vestigations on the energetics for these po-
lar contacts are ongoing. Both cyclopropyl
(in (±)-11a) and trifluoroethyl (in (±)-11b)
residues seem optimal to fill the newly
discovered hydrophobic pocket. Smaller
(as in (±)-11c,d) or larger (as in (±)-11e,f)
residues seem to fit less well, leading to a
strong reduction in binding affinity.
Cytidine derivatives 12 and 13 with a
benzimidazole tail were originally devel-
oped as inhibitors of IspD. However, they
were also shown to have moderate activity
against E. coli IspD, with K
i
values of 71 µM
and 86 µM for 12 and 13, respectively (Fig.
4a). Their substantial water-solubility al-
lowed co-crystallization with IspE from the
marine thermophile Aquifex aeolicus pro-
viding the first co-crystal structure analyses
of an IspE enzyme with synthetic ligands.
[23]
This structural information should pro-
vide valuable guidance in the future devel-
opment of new anti-infectives: In A. ae-
olicus IspE, similar to the kinases from P.
falciparum and M. tuberculosis, the Phe185
residue, lining the small, apolar pocket in
the E. coli enzyme, is substituted by a ty-
rosine residue and it seems important to ad-




methyl-D-erythritol 2-phosphate into 2C-
methyl-D-erythritol 2,4-cyclodiphosphate is
catalyzed by 2C-methyl-D-erythritol 2,4-cy-
clodiphosphate synthase (EC 4.6.1.12).
[24]
The first generation of substrate-based in-
hibitors was developed by Crane et al. with
the aim of establishing a fluorescence-
based binding assay (Fig. 5a, compounds
14a,b and 15).
[25]
It was expected that the
cytidine moiety in the ligands should oc-
cupy pocket III, in a comparable manner
to the natural substrate. Through a suitable
linker, two different fluorescent aromatic
substituents, anthranilate (2-aminobenzo-
ate) and dansyl (5,5-dimethylaminonaph-
thalenesulfamoyl), were introduced to be
accommodated by the hydrophobic cleft in
pocket II and to endow the molecules with
the required fluorescence properties. A co-
crystal structure of 14a and IspF validated
the proposed binding mode (PDB code:
2AMT, Fig. 5b). While the cytosine moiety
is anchored by four hydrogen bonds to the
backbone of the Ala100–Leu106 fragment,
the ribose is held in place by two hydrogen
bonds with Asp56’. The β-phosphate pro-




To improve the drug-like character and
the affinity of the second-generation in-
hibitors, cytosine derivatives (16a–c) and
analogues 17a,b were designed, featuring
an appropriate vector to direct the terminal
aromatic rings into pocket II (Fig. 5a).
[26]
The best inhibitors have IC
50
values in the
upper micromolar range, representing an
improvement by an order of magnitude
over the first-generation inhibitors. Hence,
it is possible to inhibit IspF without ad-
dressing the highly polar diphosphate or
ribose binding sites. As pocket II is rather
flexible, most of the binding free enthalpy
seems to be derived from the occupation
of the cytosine-binding site. A new hydro-
phobic pocket, proposed to host the central
naphthyl or methylphenyl moiety of the li-
gands, was identified and its optimal filling
is subject of ongoing investigations with the
aim to further enhance the binding affinity.
Inhibitors of IspG and IspH have not been
described so far.
3.5. IPP Isomerase
Several potent inhibitors of the IPP
isomerase (type I) have been known for
some time, ranging from fluorinated sub-
strate analogues, over mechanism-based ep-
oxides, to an ammonium derivative, which
could act as a transition state analogue.
[27]
Some of these inhibitors were crucial in
the determination of the mechanism of IPP
isomerase.
[28]
Depending on which type of
isomerase is present in a given species, this
enzyme may or may not be a suitable target
for drug design due to the potential risk of
selectivity issues.
4. Conclusions
Significant advances in terms of the elu-
cidation of the structure and mechanism of
the various enzymes of the non-mevalonate
pathway over the past two decades have set
the stage for the exploitation of the con-
stituent enzymes as targets in the develop-
ment of drugs with a novel mode of action.
This is of particular importance in light of
the emergence of multi-drug resistance in
a number of important pathogens such as
the malarial parasite P. falciparum or the
causative agent of tuberculosis, M. tuber-
culosis. While inhibitors of IspC such as
fosmydomycin have validated the pathway
as an antimalarial target and are tested in
clinical trials, progress has also been made
in the identification of drug-like, non-phos-
phate leads for the central enzymes of the
pathway, IspE and IspF. There is no doubt
that the coming years will see further en-
Fig. 5. a) Inhibitors of IspF. b) Co-crystal structure of 14a and E. coli IspF (PDB code: 2AMT).
[25]
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17a R = H 30% inhibition at [17a] = 1 mM













16a R = H IC
50
= 0.45 mM
16b R = Cl IC
50
= 0.54 mM
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hanced efforts to block the enzymes of the
non-mevalonate pathway and to shut down
isoprenoid biosynthesis in the malarial and
tuberculosis parasites.
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